Search Results
Your search for The A matches 30852 pages
Showing 1 - 50Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer
Pain, a debilitating consequence of cancer and its treatments, is highly prevalent among patients with advanced cancer.1 Often persistent and undertreated, it is associated with poor functional and emotional well-being and typically occurs along with insomnia and fatigue.2 The use of opioids, the...
Metastatic RCC After Disease Progression on VEGF/IO Therapy
This is Part 3 of Later-Line Considerations in Relapsed/Refractory Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rana McKay, Bradley McGregor, and Sumanta K. Pal discuss the management of metastatic...
Refractory RCC After Disease Progression on Adjuvant IO Therapy
This is Part 2 of Later-Line Considerations in Relapsed/Refractory Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rana McKay, Bradley McGregor, and Sumanta K. Pal discuss the management of refractory...
Metastatic Favorable-Risk RCC After Progression on VEGF/IO Therapy
This is Part 1 of Later-Line Considerations in Relapsed/Refractory Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rana McKay, Bradley McGregor, and Sumanta K. Pal discuss the management of metastatic...
Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma
Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma, according to a recent study published by Leonard-Murali et al in Nature Communications. The findings demonstrated the potential to...
The Lancet Commission on Breast Cancer: Reducing Overlooked Inequities in Breast Cancer
Investigators have uncovered persistent inequities in breast cancer that may systematically leave many patients behind in spite of recent improvements in research, treatment, and survival, according to a recent report from The Lancet Breast Cancer Commission. These findings were published by Coles...
A Pioneering Female Oncologist in Morocco Helps Advance the Global Shift Toward Gender Equity in Academia
Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation of researchers and practitioners and enrich global oncology. I recently had the privilege to speak with Ouissam Al Jarroudi, MD, about her...
Cisplatin, Gemcitabine, and IMRT in Locally Advanced Vulvar Cancer
In a phase II trial (NRG Oncology/GOG Study 279) reported in the Journal of Clinical Oncology, Horowitz et al found that concurrent cisplatin, gemcitabine, and intensity-modulated radiation therapy (IMRT) produced a high rate of complete pathologic response in patients with locally advanced vulvar...
HER2-Positive Early Breast Cancer: PET-Based, pCR-Adapted Strategy
In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response (pCR)-adapted treatment strategy produced “excellent” 3-year invasive disease–free survival results in patients with HER2-positive early...
Cabozantinib in Advanced Adrenocortical Carcinoma
In a single-center phase II trial reported in The Lancet Oncology, Campbell et al found that cabozantinib monotherapy showed activity in adult patients with advanced adrenocortical carcinoma. Study Details In the trial, 18 patients enrolled at The University of Texas MD Anderson Cancer Center...
Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer
The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type, homologous recombination deficiency (HRD)-positive tumors, according to data presented during the Society of...
New Findings Suggest No Correlation Between GLP-1 Receptor Agonists and Thyroid Cancer Risk
Glucagon-like peptide (GLP)-1 receptor agonists may not be associated with an increased risk of thyroid cancer, according to a recent study published by Pasternak et al in the BMJ. Background GLP-1 receptor agonists are designed to reduce blood sugar levels and appetite. They have become...
Study Identifies Genetic Variants Potentially Linked to Prevalent or Persistent HPV Infections
Investigators have uncovered genetic variants that may predispose certain female patients to prevalent or persistent human papillomavirus (HPV) infections and increase their risk of developing cervical cancer, according to a recent study published by Adebamowo et al in the European Journal of Human ...
Exploring Geriatric Assessment Effectiveness: Insights From the 2023 International Society of Geriatric Oncology Conference
Geriatric assessment has emerged as a pivotal tool in optimizing cancer care for older patients, aiming to mitigate treatment toxicity, enhance treatment adherence, and improve quality of life. The recommended areas for evaluation in a geriatric assessment focus on identifying health issues that...
Newly Diagnosed Locally Advanced HNSCC: Adding Pembrolizumab to Concurrent Chemoradiotherapy
As reported in The Lancet Oncology by Jean-Pascal Machiels, MD, and colleagues, the phase III KEYNOTE-412 trial showed no significant improvement in event-free survival with the addition of pembrolizumab to concurrent chemoradiotherapy in newly diagnosed patients with high-risk locally advanced...
Oxaliplatin-Based Adjuvant Therapy in Older Patients With Stage III Colon Cancer
In a pooled analysis of data from clinical trials in the ACCENT/IDEA databases reported in the Journal of Clinical Oncology, Claire Gallois, MD, and colleagues found that patients aged ≥ 70 years receiving oxaliplatin-based adjuvant chemotherapy for stage III colon cancer had a similar time to...
Illuminating a Potential Culprit in Melanoma Treatment Resistance
Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma, according to a recent study published by Aya Moreno et al in Cell Reports. Background The global incidence of melanoma—the deadliest type of skin cancer—is rising, making novel...
Radon Gas Exposure May Be Linked to Increased Incidence of Lung Cancer in Nonsmokers
Long-term exposure to radon gas may be associated with a rise in nonsmoking lung cancer cases, according to a recent consumer survey conducted on behalf of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James)....
B-Cell Non-Hodgkin Lymphoma: Extended Follow-up With Mosunetuzumab
As reported in the Journal of Clinical Oncology by L. Elizabeth Budde, MD, PhD, and colleagues, extended follow-up of the dose-escalation phase of a phase I/II trial showed that the CD20 x CD3 T-cell–engaging bispecific antibody mosunetuzumab-axgb—given as an off-the-shelf fixed-duration outpatient ...
Lung Cancer Screening Eligibility: Effect of Using History vs Pack-Year History of Smoking
In a study reported in the Journal of Clinical Oncology, Potter et al found that use of a smoking history of ≥ 20 years rather than the current 2021 U.S. Preventive Services Task Force (USPSTF) guideline of ≥ 20 pack-years would increase the eligibility of Black individuals for lung cancer...
Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer
Researchers have found that a novel urine biomarker test may effectively halve the number of cystoscopies necessary in high-risk patients with bladder cancer, according to recent findings presented by Dreyer et al at the European Association of Urology (EAU) Congress 2024. The research also...
Longer Interval May Be Safe for Prostate Cancer Screening in Low-Risk Patients
Undergoing a prostate-specific antigen (PSA) blood test every 5 years may be adequate for screening low-risk men for prostate cancer, according to recent findings presented by Albers et al at the European Association of Urology (EAU) Congress 2024 and simultaneously published in European Urology....
The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040
Investigators have projected impending increases in the incidence and mortality rates of prostate cancer—especially among individuals in low- and middle-income countries—and proposed new strategies to improve screening, awareness, research diversification, and treatment in a recent The Lancet...
Blood-Based Machine-Learning Assay May Noninvasively Detect Early Ovarian Cancer
Ovarian cancer is the eighth most-common cancer among women globally, and the eighth most-common cause of death from cancer worldwide. In the United States alone, in 2023, there were nearly 20,000 new cases of the cancer, and about 13,270 deaths from the disease. Ovarian cancer is largely...
Effect of Virtually Delivered CBT for Insomnia on Cancer-Related Cognitive Impairment
In a Canadian study reported in the Journal of Clinical Oncology, Sheila N. Garland, PhD, and colleagues found that virtually delivered cognitive behavioral therapy for insomnia (CBT-I) improved perceived cancer-related cognitive impairment (CRCI) vs waiting list controls in cancer survivors. Study ...
Anti-CD19 CAR T-Cell Therapy for Richter Transformation
In a retrospective study reported in the Journal of Clinical Oncology, Kittai et al found that anti-CD19 chimeric antigen receptor (CAR) T-cell therapy showed activity in previously treated patients with Richter transformation. Study Details In the study, 69 patients who received CAR T-cell therapy ...
Educational Videos May Encourage Prostate Cancer Screening Among Black Patients
Use of culturally sensitive educational videos may boost knowledge and decrease uncertainty regarding prostate cancer and screening among Black individuals, according to new findings presented by Jones et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...
BAP1 Mutations May Increase Susceptibility to Asbestos-Induced Malignant Mesothelioma
Researchers have shown that even minimal exposure to chrysotile asbestos may increase susceptibility to the development of malignant mesothelioma in mice with BAP1 germline mutations, according to new findings presented by Kadariya et al at the American Association for Cancer Research (AACR) Annual ...
Ana Oaknin, MD, PhD, on Recurrent Cervical Cancer: New Findings on Atezolizumab, Bevacizumab, and Chemotherapy
Ana Oaknin, MD, PhD, of Spain’s Vall d’Hebron University Hospital, discusses phase III findings from the BEATcc trial, showing that adding atezolizumab to a standard bevacizumab-plus-platinum regimen for patients with metastatic, persistent, or recurrent cervical cancer significantly improves...
An Exosome-Based Liquid Biopsy for Early Detection of Pancreatic Cancer
An investigational exosome-based liquid biopsy accurately detected 97% of stage I to II pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract 3899). “Pancreatic cancer is one...
Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations
Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...
AACR Inaugurates New Leadership
The members of the American Association for Cancer Research (AACR) elected a new 2024 to 2025 President and President-Elect at the AACR’s Annual Business Meeting of Members during the AACR Annual Meeting 2024 in San Diego. New President The AACR welcomed Patricia M. LoRusso, DO, PhD (hc), FAACR, as ...
PARP1-Selective Inhibitor in HRR-Deficient Breast Cancer
The novel poly-ADP ribose polymerase-1 (PARP1)-selective inhibitor saruparib demonstrated early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancer, according to new findings presented by Yap et al at the American Association for...
Investigational Personalized Vaccine in Resected Head and Neck Cancers
TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected human papillomavirus (HPV)-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association...
ATM Kinase Inhibitor Plus Radiotherapy for Patients With Glioblastoma
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in patients with both recurrent and newly diagnosed glioblastoma when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in patients with recurrent...
Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer
The combination of the KRAS G12C inhibitor adagrasib and the anti-EGFR antibody cetuximab showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer, according to results from the phase I/II KRYSTAL-1...
Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer
SYNC-T—an investigational therapy that combines a device-induced vaccination at the tumor site with an intratumoral infusion of a multitarget biologic drug—led to numerous clinical responses in patients with metastatic castration-resistant prostate cancer, according to results reported at the...
Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate With Clinical Benefit
An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk of disease recurrence in certain patients with resectable pancreatic cancer,...
Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer—including those with PD-L1–low tumors—compared with...
RP1 Immunotherapy in Solid Organ Transplant Recipients With Skin Cancer
A novel oncolytic immunotherapy may show antitumor activity in solid organ transplant recipients with skin cancer, according to new findings presented by Migden et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT003). Background "Organ transplant recipients ...
Novel CAR T-Cell Therapy May Show Benefit in Patients With Advanced Clear Cell Renal Cell Carcinoma
The CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy CTX130 may be effective in patients with advanced clear cell renal cell carcinoma, according to findings presented by Srour et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT002)...
Ciltacabtagene Autoleucel and Idecabtagene Vicleucel Approved by the FDA for Pretreated Patients With Multiple Myeloma
On April 5, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and...
Mirvetuximab Soravtansine Plus Pembrolizumab in Patients With Endometrial Cancer Subtype
The combination of the antibody-drug conjugate mirvetuximab soravtansine-gynx and the immune checkpoint inhibitor pembrolizumab showed notable activity in patients with recurrent or persistent microsatellite-stable endometrial cancer, according to new findings presented by Porter et al at the...
Can a Personalized Antitumor Vaccine Plus Pembrolizumab Improve Outcomes in Hepatocellular Carcinoma?
Adding a personalized antitumor vaccine to the PD-1 inhibitor pembrolizumab may be safe and about twice as effective at shrinking tumors in patients with hepatocellular carcinoma compared with pembrolizumab alone, according to new findings presented by Yarchoan et al at the American Association for ...
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors
On April 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no...
Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations
According to recent studies, the incidence of early-onset cancers—often defined as those diagnosed in individuals younger than age 50—is on the rise, and not just in the United States but globally as well. Research shows that between 1990 and 2019, the global incidence of early-onset cancer...
Fewer Than Half of Drugs Granted Accelerated Approval Demonstrated Benefit Within 5 Years
In 1992, the U.S. Food and Drug Administration (FDA) instituted its Accelerated Approval regulations, which allow drugs that treat serious conditions and fill an unmet need to be approved early based on a surrogate endpoint. However, any drug approved under this pathway is still required to undergo ...
Improving Adjuvant Treatment in Patients With Muscle-Invasive Urothelial Carcinoma
Two recent studies have offered new insights into the treatment of muscle-invasive urothelial carcinoma following cystectomy, according to findings presented by Powles et al and Galsky et al at the European Association of Urology Congress 2024. The research could allow physicians to target...
Distinct Microbial Signature Uncovered in KRAS-Mutated Colorectal Cancer
Researchers have identified microbiota signatures that are associated with KRAS mutations in patients with colorectal cancer, according to a recent study published by Huang et al in Microbiology Spectrum. The findings suggest that gut microbes may serve as a noninvasive biomarker for subtypes of...
American Cancer Society Releases Latest Global Cancer Statistics; Cancer Cases Expected to Rise to 35 Million Worldwide by 2050
The American Cancer Society (ACS) has released Global Cancer Statistics 2022, an update of the organization’s report on global cancer facts and trends. According to the findings, an estimated 20 million cancer cases were newly diagnosed in 2022 and 9.7 million people died from the disease...
